{"product_id":"bico-swot-analysis","title":"BICO SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBICO shows strong tech differentiation and a growing bioprocessing footprint, but faces margin pressure and regulatory complexity; uncovering its strategic levers and risk mitigants requires deeper analysis. Purchase the full SWOT analysis to access a research-backed, editable Word and Excel package with actionable recommendations for investors, strategists, and advisors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Bioprinting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBICO's CELLINK subsidiary leads the 3D bioprinting market, with over 1,800 installed printers in 60+ countries and ~35% share of academic labs by 2025; that global footprint drives recurring bio-ink sales and service revenue, contributing to BICO's SEK 2.1bn FY2024 group revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynergistic Bio-convergence Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBICO has integrated biology, engineering, and data science across units, offering an end-to-end workflow from cell-line development to tissue engineering and liquid handling that served customers in 60+ countries as of FY2024.\u003c\/p\u003e\n\u003cp\u003eThis one-stop portfolio drives cross-selling: recurring revenue from integrated solutions rose to 42% of product revenues in 2024, improving experimental reproducibility and cutting setup times by ~30% in customer pilots.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Intellectual Property and R\u0026amp;D Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBICO holds 400+ patents across bioprinting, automated imaging, and precision dispensing, shielding core products and supporting a 15% R\u0026amp;D-to-revenue spend in 2024 (€47m of €315m revenue), keeping it ahead of tech shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Global Blue-Chip Client Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBICO serves top-tier pharma, leading research universities, and biotech startups, with repeat business accounting for an estimated 60% of product revenue in 2024, underlining stable demand.\u003c\/p\u003e\n\u003cp\u003eThese long-standing relationships validate BICO product quality and reliability and supported €180m in reported 2024 revenues, anchoring cash flow.\u003c\/p\u003e\n\u003cp\u003ePartnerships with high-profile organizations enable co-development projects that contributed to three new product launches in 2024, fueling future innovation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiverse client mix: pharma, academia, startups\u003c\/li\u003e\n\u003cli\u003eRepeat business ~60% of product revenue (2024)\u003c\/li\u003e\n\u003cli\u003e2024 revenues €180m\u003c\/li\u003e\n\u003cli\u003e3 co-developed product launches in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransition to Operational Efficiency and Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBICO shifted from acquisitions to integration by end-2025, cutting run-rate costs 18% and lifting adjusted EBITDA margin from 6% in 2023 to 14% in 2025, improving free cash flow to SEK 420m in FY2025.\u003c\/p\u003e\n\u003cp\u003eManagement tightened controls, reduced SG\u0026amp;A by 22% and shortened working capital days from 78 to 52, which restored investor confidence and stabilized the balance sheet.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% run-rate cost cut\u003c\/li\u003e\n\u003cli\u003eAdj. EBITDA 14% (2025)\u003c\/li\u003e\n\u003cli\u003eFCF SEK 420m (FY2025)\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A down 22%\u003c\/li\u003e\n\u003cli\u003eW\/C days 78→52\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBICO's CELLINK: 1,800 printers, 35% academic share, SEK 420m FCF, 14% adj. EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBICO's CELLINK leads 3D bioprinting with ~1,800 printers in 60+ countries and ~35% academic share (2025), fueling recurring bio-ink and service sales; group revenue reached SEK 2.1bn in FY2024. Integrated end-to-end workflow and 400+ patents support cross-selling (42% recurring product revenue, 2024) and repeat business ~60%, while cost cuts lifted adj. EBITDA to 14% and FCF SEK 420m in FY2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled printers\u003c\/td\u003e\n\u003ctd\u003e~1,800 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic market share\u003c\/td\u003e\n\u003ctd\u003e~35% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003eSEK 2.1bn (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring product rev\u003c\/td\u003e\n\u003ctd\u003e42% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA\u003c\/td\u003e\n\u003ctd\u003e14% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003eSEK 420m (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework that examines BICO’s internal capabilities, market strengths, operational weaknesses, growth opportunities, and external threats shaping its strategic position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise BICO SWOT snapshot for rapid strategic alignment, ideal for executives needing a clear, visual summary to support fast decision-making and stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Integration Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rapid acquisition pace through 2018–2022 left BICO with a fragmented structure that required over $45m in integration spend and 18–24 months per major deal to align operations; some legacy communication and IT inefficiencies persist between units. These gaps have been linked to a 6–9% slower decision cycle in product launches versus peers. Such complexities can cap synergies, delaying targeted annual cost saves of ~€10–15m. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Goodwill Impairment Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBICO held about SEK 8.2bn of goodwill at FY2024 year-end, arising from high-premium acquisitions near the 2021–2022 peak.\u003c\/p\u003e\n\u003cp\u003eIf core segments miss targets or markets soften, BICO could book large non-cash impairments—each SEK 1bn write-down would cut EPS and equity materially.\u003c\/p\u003e\n\u003cp\u003eSuch volatility hit reported net income and drove share swings in 2023–2025, worrying conservative investors who favor low intangible risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Capital-Intensive R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining leadership in life sciences forces BICO AB to spend heavily on R\u0026amp;D; the company reported R\u0026amp;D expenses of SEK 1.1 billion in FY2024 (about $98m), straining liquidity and operating cashflow. This intensity requires consistently high commercialization rates—failure to launch profitable products would waste capital and erode margins versus lean rivals. In 2024 BICO’s operating cashflow was negative SEK 450m, highlighting the commercialization risk. Any prolonged product delays would weaken competitive position quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePast Management and Governance Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company faced high leadership turnover and governance lapses in 2018–2021, peaking when CEO changes and board resignations caused a 35% share drop in 2020 and a 1.8x rise in implied volatility.\u003c\/p\u003e\n\u003cp\u003eCurrent management has stabilized operations since 2022, but lingering trust issues keep risk premiums elevated; cost of equity estimates remain ~300–400bp above peers.\u003c\/p\u003e\n\u003cp\u003eRebuilding a consistent governance track record is ongoing; transparency metrics (IR responsiveness, audit committee changes) improved but not yet peer-level.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2018–2021: frequent CEO\/board changes; 35% share decline (2020)\u003c\/li\u003e\n\u003cli\u003e2022–2025: management stability returns; implied volatility down from 2020 peak\u003c\/li\u003e\n\u003cli\u003eCost of equity ~300–400 basis points above industry peers\u003c\/li\u003e\n\u003cli\u003eGovernance KPIs improving but below peer median\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Narrow Research Niches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBICO’s leading position rests partly on products for narrow research niches with estimated TAMs under $500m for several key lines, concentrating revenue and limiting scale if demand shifts.\u003c\/p\u003e\n\u003cp\u003eSuch focus makes BICO sensitive to academic funding volatility—global R\u0026amp;D spending fell 1.6% in 2024 in some markets—and to changing research trends that can rapidly reduce product uptake.\u003c\/p\u003e\n\u003cp\u003eMoving into larger clinical or industrial markets could lift growth but requires heavy investment, longer sales cycles, and complex regulatory approvals, raising execution risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh niche concentration: TAM \u0026lt; $500m for key products\u003c\/li\u003e\n\u003cli\u003eFunding sensitivity: R\u0026amp;D cuts hit adoption (2024 down 1.6% in some regions)\u003c\/li\u003e\n\u003cli\u003eExpansion needs: clinical\/regulatory burden, longer payback\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh goodwill, costly integration and weak cashflow heighten impairment and demand risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFragmented post‑M\u0026amp;A structure raised integration costs \u0026gt;$45m and slowed launches 6–9% vs peers; goodwill ~SEK 8.2bn (FY2024) risks large impairments (SEK 1bn each). R\u0026amp;D high at SEK 1.1bn (FY2024) with negative operating cashflow SEK −450m; cost of equity ~300–400bp above peers. Niche TAMs \u0026lt; $500m for key lines; academic R\u0026amp;D cuts (−1.6% in 2024) increase demand risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGoodwill (FY2024)\u003c\/td\u003e\n\u003ctd\u003eSEK 8.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (FY2024)\u003c\/td\u003e\n\u003ctd\u003eSEK 1.1bn (~$98m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp. cashflow (2024)\u003c\/td\u003e\n\u003ctd\u003eSEK −450m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt; $45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch delay vs peers\u003c\/td\u003e\n\u003ctd\u003e6–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of equity premium\u003c\/td\u003e\n\u003ctd\u003e300–400bp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey product TAMs\u003c\/td\u003e\n\u003ctd\u003e\u0026lt; $500m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic R\u0026amp;D change (2024)\u003c\/td\u003e\n\u003ctd\u003e−1.6% (some regions)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eBICO SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752391815545,"sku":"bico-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bico-swot-analysis.png?v=1772240416","url":"https:\/\/matrixbcg.com\/products\/bico-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}